Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Conditions:   Adult Solid Neoplasm;   Malignant Reproductive System Neoplasm;   Malignant Urinary System Neoplasm;   Metastatic Malignant Neoplasm;   Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter;   Progressive Neoplastic Disease;   Recurrent Bladder Carcinoma;   Recurrent Urethra Carcinoma;   Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter;   Regional Urothelial Carcinoma of the Renal Pelvis and Ureter;   Stage III Bladder Urothelial Carcinoma;   Stage III Urethral Cancer;   Stage IV Bladder Urothelial Carcinoma;   Stage IV Urethral Cancer;   Urethral Urothelial CarcinomaInterventions:   Drug: Cabozantinib S-malate;   Biological: Nivolumab;   Biological: Ipilimumab;   Other: Laboratory Biomarker AnalysisSponsor:   National Cancer Institute (NCI)Not yet recruiting - verified December 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials